Compare Levi Strauss & Co. (LEVI) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

Levi Strauss & Co. (LEVI) trades at $24.56, up 0.82% on the day, with strong analyst support (83% Buy rating) and a consensus price target of $28.00. Recent quarterly earnings have consistently beaten expectations, including a Q2 2026 EPS of $0.28 versus $0.24 expected, driven by robust direct-to-consumer growth. The company maintains solid profitability with a 61.72% gross margin and 9.66% net margin, while technical indicators show a bearish overall signal despite bullish moving averages.

The outlook is positive given earnings momentum and raised full-year guidance, though near-term stock performance faces headwinds from tariff concerns and foreign exchange pressures. Investment appeal lies in its digital strategy execution and dividend growth, with risks including competitive pressures and macroeconomic volatility affecting consumer spending.

Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% today, with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 EPS of $1.94 beating expectations by 59%, revenue growth to $3.1B in 2026, and net income margin expanding to 21.55%. Recent news highlights executive appointments and positive clinical trial updates for crinecerfont, supporting growth prospects.

Outlook remains positive with 86% analyst buy ratings and a $196.08 consensus price target implying 13% upside. Key risks include execution of pipeline developments and integration of acquisitions. The stock's valuation at P/E 26.62 appears reasonable given earnings growth trajectory and strong profitability metrics.